Monopar Therapeutics Inc (MNPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) has a cash flow conversion efficiency ratio of -0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.72 Billion) by net assets ($130.85 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Monopar Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Monopar Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Monopar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Monopar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monopar Therapeutics Inc ranked by their cash flow conversion efficiency. See MNPR cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dalian Demaishi Precision Technology Co.Ltd
SHE:301007
|
0.043x |
|
Actblue Co Ltd
SHE:300816
|
0.050x |
|
Whirlpool S.A
SA:WHRL3
|
0.421x |
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
-0.002x |
|
Tanla Platforms Limited
NSE:TANLA
|
0.074x |
|
Ridley Corporation Ltd
AU:RIC
|
0.154x |
|
BOROSIL RENEWABLES LIMITED
NSE:BORORENEW
|
0.152x |
|
HIVE Digital Technologies Ltd.
V:HIVE
|
0.082x |
Annual Cash Flow Conversion Efficiency for Monopar Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Monopar Therapeutics Inc from 2015 to 2025. View Monopar Therapeutics Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $137.83 Million | $-12.20 Million | -0.089x | +23.92% |
| 2024-12-31 | $55.04 Million | $-6.40 Million | -0.116x | +91.73% |
| 2023-12-31 | $5.59 Million | $-7.86 Million | -1.406x | -96.30% |
| 2022-12-31 | $10.09 Million | $-7.23 Million | -0.716x | -85.45% |
| 2021-12-31 | $18.94 Million | $-7.32 Million | -0.386x | -30.03% |
| 2020-12-31 | $15.69 Million | $-4.66 Million | -0.297x | -24.33% |
| 2019-12-31 | $12.63 Million | $-3.02 Million | -0.239x | +42.73% |
| 2018-12-31 | $6.92 Million | $-2.89 Million | -0.417x | -52.76% |
| 2017-12-31 | $9.62 Million | $-2.63 Million | -0.273x | +35.27% |
| 2016-12-31 | $2.83 Million | $-1.19 Million | -0.422x | -82.64% |
| 2015-12-31 | $2.75 Million | $-636.33K | -0.231x | -- |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more